<DOC>
	<DOCNO>NCT01754974</DOCNO>
	<brief_summary>The purpose study determine 48 week therapy Peginterferon Lambda plus Ribavirin effective safe treatment chronic hepatitis C ( CHC ) compare therapy Peginterferon alfa-2a plus Ribavirin .</brief_summary>
	<brief_title>Safety Efficacy Study Peginterferon Lambda-1a vs. Peginterferon Alfa-2a , Plus Ribavirin Subjects With Genotype 1 Hepatitis C</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Chronic hepatitis C , Genotype 1 HCV RNA ≥100,000 IU/mL screen Liver biopsy document cirrhosis ( within prior 3 year ) . Where approve stag liver disease , noninvasive imaging may use assess extent liver disease Naïve prior antiHCV therapy Infected HCV Genotype 1 Positive Hepatitis B Surface Antigen ( HBsAg ) , Human Immunodeficiency Virus ( HIV ) 1/HIV2 antibody screen Evidence liver disease HCV Active substance abuse Use hematologic growth factor within 90 day prior study randomization Evidence history cirrhosis base radiologic criterion biopsy result clinical criterion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>